Literature DB >> 25965974

Functional screening identifies MCT4 as a key regulator of breast cancer cell metabolism and survival.

Franziska Baenke1, Sébastien Dubuis2, Charlene Brault3, Britta Weigelt4, Beatrice Dankworth3, Beatrice Griffiths1, Ming Jiang5, Alan Mackay6, Becky Saunders5, Bradley Spencer-Dene7, Susana Ros1, Gordon Stamp7, Jorge S Reis-Filho4, Michael Howell5, Nicola Zamboni3, Almut Schulze1,3,8.   

Abstract

Metabolic reprogramming in cancer enhances macromolecule biosynthesis and supports cell survival. Oncogenic drivers affect metabolism by altering distinct metabolic processes and render cancer cells sensitive to perturbations of the metabolic network. This study aimed to identify selective metabolic dependencies in breast cancer by investigating 17 breast cancer cells lines representative of the genetic diversity of the disease. Using a functional screen, we demonstrate here that monocarboxylate transporter 4 (MCT4) is an important regulator of breast cancer cell survival. MCT4 supports pH maintenance, lactate secretion and non-oxidative glucose metabolism in breast cancer cells. Moreover, MCT4 depletion caused an increased dependence of cancer cells on mitochondrial respiration and glutamine metabolism. MCT4 depletion reduced the ability of breast cancer cells to grow in a three-dimensional (3D) matrix or as multilayered spheroids. Moreover, MCT4 expression is regulated by the PI3K-Akt signalling pathway and highly expressed in HER2-positive breast cancers. These results suggest that MCT4 is a potential therapeutic target in defined breast cancer subtypes and reveal novel avenues for combination treatment.
Copyright © 2015 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Entities:  

Keywords:  HER2; MCT4; PI3K-Akt pathway; breast cancer; lactate; metabolism

Mesh:

Substances:

Year:  2015        PMID: 25965974     DOI: 10.1002/path.4562

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  31 in total

Review 1.  Monocarboxylate Transporters: Therapeutic Targets and Prognostic Factors in Disease.

Authors:  R S Jones; M E Morris
Journal:  Clin Pharmacol Ther       Date:  2016-08-22       Impact factor: 6.875

2.  Co-culture With Human Breast Adipocytes Differentially Regulates Protein Abundance in Breast Cancer Cells.

Authors:  Rebekah Lee Isla Crake; Elisabeth Phillips; Torsten Kleffmann; Margaret Jane Currie
Journal:  Cancer Genomics Proteomics       Date:  2019 Sep-Oct       Impact factor: 4.069

Review 3.  Causes, consequences, and therapy of tumors acidosis.

Authors:  Smitha R Pillai; Mehdi Damaghi; Yoshinori Marunaka; Enrico Pierluigi Spugnini; Stefano Fais; Robert J Gillies
Journal:  Cancer Metastasis Rev       Date:  2019-06       Impact factor: 9.264

Review 4.  Pathophysiological role of ion channels and transporters in HER2-positive breast cancer.

Authors:  Zhengxing Zhou; Chengmin Zhang; Zhiyuan Ma; Hu Wang; Biguang Tuo; Xiaoming Cheng; Xuemei Liu; Taolang Li
Journal:  Cancer Gene Ther       Date:  2022-01-07       Impact factor: 5.854

5.  Branched-chain ketoacids secreted by glioblastoma cells via MCT1 modulate macrophage phenotype.

Authors:  Lidia Santos Silva; Gernot Poschet; Yannic Nonnenmacher; Holger M Becker; Sean Sapcariu; Ann-Christin Gaupel; Magdalena Schlotter; Yonghe Wu; Niclas Kneisel; Martina Seiffert; Rüdiger Hell; Karsten Hiller; Peter Lichter; Bernhard Radlwimmer
Journal:  EMBO Rep       Date:  2017-10-24       Impact factor: 8.807

Review 6.  Monocarboxylate Transporters (SLC16): Function, Regulation, and Role in Health and Disease.

Authors:  Melanie A Felmlee; Robert S Jones; Vivian Rodriguez-Cruz; Kristin E Follman; Marilyn E Morris
Journal:  Pharmacol Rev       Date:  2020-04       Impact factor: 25.468

7.  Use of signals of positive and negative selection to distinguish cancer genes and passenger genes.

Authors:  László Bányai; Maria Trexler; Krisztina Kerekes; Orsolya Csuka; László Patthy
Journal:  Elife       Date:  2021-01-11       Impact factor: 8.140

8.  MCT1 Inhibitor AZD3965 Increases Mitochondrial Metabolism, Facilitating Combination Therapy and Noninvasive Magnetic Resonance Spectroscopy.

Authors:  Mounia Beloueche-Babari; Slawomir Wantuch; Teresa Casals Galobart; Markella Koniordou; Harold G Parkes; Vaitha Arunan; Yuen-Li Chung; Thomas R Eykyn; Paul D Smith; Martin O Leach
Journal:  Cancer Res       Date:  2017-09-18       Impact factor: 12.701

Review 9.  Overcoming Hypoxia-Mediated Tumor Progression: Combinatorial Approaches Targeting pH Regulation, Angiogenesis and Immune Dysfunction.

Authors:  Paul C McDonald; Shawn C Chafe; Shoukat Dedhar
Journal:  Front Cell Dev Biol       Date:  2016-03-31

10.  Mutant IDH1 expression is associated with down-regulation of monocarboxylate transporters.

Authors:  Pavithra Viswanath; Chloe Najac; Jose L Izquierdo-Garcia; Aleksandr Pankov; Chibo Hong; Pia Eriksson; Joseph F Costello; Russell O Pieper; Sabrina M Ronen
Journal:  Oncotarget       Date:  2016-06-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.